[CAS NO. 1190094-64-4]  CP-609754

Ships within Stock Price Qty Total
$0.00
$0.00
Please click "REQUEST A QUOTE" button if you need other sizes or custom synthesis
request a quote
If there is no stock, or you need other sizes or custom synthesis, please:

PRODUCTS SPECIFICATIONS [1190094-64-4]

Catalog
HY-16373
Brand
MCE
CAS
1190094-64-4

DESCRIPTION [1190094-64-4]

Overview

MDL-
Molecular Weight479.96
Molecular FormulaC29H22ClN3O2
SMILESO=C1N(C)C2=C(C=C([C@](O)(C3=CC=C(Cl)C=C3)C4=CN=CN4C)C=C2)C(C5=CC=CC(C#C)=C5)=C1

For research use only. We do not sell to patients.

Summary

CP-609754 (LNK-754) is a potent and reversible farnesyltransferase inhibitor with potential anticancer activity.The IC 50 for inhibiting farnesylation of recombinant human H-Ras is 0.57 ng/mL and recombinant K-Ras is 46 ng/mL [1] .


In Vitro

CP-609754 (CP-609,754) is a reversible inhibitor of farnesyltransferase with a slow on/off rate. CP-609,754 inhibits farnesylation (IC 50 =1.72 ng/mL) of mutant H-Ras in 3T3 H-ras (61L)-transfected cell lines with SDS-PAGE analysis of [ 35 S]methionine-labeled material [1] .
CP-609754 is competitive for the prenyl acceptor (H-Ras protein) and noncompetitive for the prenyl donor farnesyl PPI. CP-609754 interacts with the farnesyltransferase-farnesyl PPI complex and competes for the binding of the Ras protein. CP-609754 selectively inhibits farnesylation of both H- and K-Ras proteins in 3T3 transfectants [1] .

MCE has not independently confirmed the accuracy of these methods. They are for reference only.


In Vivo

CP-609754 (CP-609,754) has antitumor activity against 3T3 H-ras (61L) tumors in vivo [1] .
With twice daily oral dosing of CP-609754, tumor regression is achieved with a dose of 100 mg/kg; the ED 50 for tumor growth inhibition is 28 mg/kg [1] .
With continuous i.p. infusion of CP-609754, tumor growth is inhibited by >50%, and tumor farnesyltransferase activity inhibited by >30% in mice in which the plasma concentration of CP-609754 is maintained above 118 ng/mL [1] .

MCE has not independently confirmed the accuracy of these methods. They are for reference only.


Clinical Trial

NCT Number Sponsor Condition Start Date Phase
NCT01013610 Link Medicine Corporation
Mild Alzheimer´s Disease
November 2009 Phase 1
NCT00903253 Link Medicine Corporation
Healthy Elderly Volunteers
May 2009 Phase 1

Appearance

Solid


Shipping

Room temperature in continental US; may vary elsewhere.


Storage

Powder -20°C 3 years
4°C 2 years
In solvent -80°C 6 months
-20°C 1 month

Solvent & Solubility

In Vitro:

DMSO : 100 mg/mL ( 208.35 mM ; Need ultrasonic)

Preparing
Stock Solutions
Concentration Solvent Mass 1 mg 5 mg 10 mg
1 mM 2.0835 mL 10.4175 mL 20.8351 mL
5 mM 0.4167 mL 2.0835 mL 4.1670 mL
10 mM 0.2084 mL 1.0418 mL 2.0835 mL
* Please refer to the solubility information to select the appropriate solvent.
In Vivo:
  • 1.

    Add each solvent one by one: 10% DMSO >> 40% PEG300 >> 5% Tween-80 >> 45% saline

    Solubility: ≥ 2.5 mg/mL (5.21 mM); Clear solution

  • 2.

    Add each solvent one by one: 10% DMSO >> 90% corn oil

    Solubility: ≥ 2.5 mg/mL (5.21 mM); Clear solution

* All of the co-solvents are available by MCE.